Are Chinese herbal medicine trials for acute stroke less likely to report safety than Western trials?
A 2026 review compared how Chinese herbal medicine (CHM) trials and Western medicine (WM) trials report outcomes in acute stroke. The review found that CHM trials are much less likely to report safety information than WM trials. This difference makes it harder to know the risks of CHM treatments.
What the research says
A 2026 review looked at 306 randomized controlled trials for acute stroke published between 2020 and 2024 36. Of these, 135 were CHM trials and 171 were WM trials. The review found that only 49.63% of CHM trials reported safety outcomes, compared to 83.63% of WM trials 36. This means that about half of CHM trials did not tell readers about side effects or harms. The review also found that CHM trials were less likely to define a primary outcome: only 7.41% of CHM trials did so, versus 45.61% of WM trials 36. Without a clear primary outcome, it is harder to judge whether a treatment works. These findings are consistent with earlier Cochrane reviews of specific Chinese herbal medicines for stroke, which noted that many trials did not adequately report safety 78.
What to ask your doctor
- What safety information is available for the Chinese herbal medicine I am considering?
- Has this herbal medicine been tested in trials that reported side effects?
- How does the evidence for this herbal medicine compare to standard Western treatments for stroke?
- Are there any known interactions between this herbal medicine and my current medications?
This question is drawn from common patient questions about Neurology and answered using cited medical research. We do not provide individualized advice.